Prognostic Factors and Functionality in Metastatic Spinal Cord Compression: Cohort Study
Introduction: Metastatic Spinal Cord Compression (MSCC) has great potential of irreversible loss of motor and sensory function, and it is considered an oncological emergency. Objective: Evaluate the prognosis of MSCC and the functionality of patients with solid tumors. Method: Cohort study was condu...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | Brasil |
| Institución: | Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
| Repositorio: | Revista Brasileira de Cancerologia (Online) |
| Idioma: | portugués inglés |
| OAI Identifier: | oai:rbc.inca.gov.br:article/2160 |
| Acceso en línea: | https://rbc.inca.gov.br/index.php/revista/article/view/2160 |
| Access Level: | acceso abierto |
| Palabra clave: | compressão da medula espinal neoplasias da coluna vertebral metástase neoplásica prognóstico spinal cord compression spinal neoplasms neoplasm metastasis prognosis compresión de la médula espinal neoplasias de la columna vertebral metástasis de la neoplasia pronósticos |
| Sumario: | Introduction: Metastatic Spinal Cord Compression (MSCC) has great potential of irreversible loss of motor and sensory function, and it is considered an oncological emergency. Objective: Evaluate the prognosis of MSCC and the functionality of patients with solid tumors. Method: Cohort study was conducted in patients with cancer who developed MSCC between January 2017 and December 2018. Clinical and socio-demographic data were extracted from physical and electronic charts. Survival analysis was performed by the Kaplan-Meier method. Results: The study included 90 patients who were diagnosed with MSCC. At the time of MSCC diagnosis, 55.5% of patients were unable to walk. Patients with MSCC after lung cancer had 4.1-fold more odds of death (95% CI: 1.79-9.41; p=0.001), those with genitourinary tumors, 1.9-fold higher risk of death (95% CI: 1.06-3.45; p=0,02), and with other types of tumors, 3.1-fold higher risk of death (95% CI: 1.58-6.24; p=0.001) when compared with patients with MSCC after breast cancer. Conclusion: The clinical relevance of this study relies on the findings that the primary type of tumor is a predictive factor for overall survival of MSCC. More than half of the patients were unable to walk at the MSCC diagnosis. |
|---|